PL2621477T3 - Doustna tabletka farmaceutyczna do kontrolowanego uwalniania mesalazyny i sposób jej wytwarzania - Google Patents

Doustna tabletka farmaceutyczna do kontrolowanego uwalniania mesalazyny i sposób jej wytwarzania

Info

Publication number
PL2621477T3
PL2621477T3 PL11805527T PL11805527T PL2621477T3 PL 2621477 T3 PL2621477 T3 PL 2621477T3 PL 11805527 T PL11805527 T PL 11805527T PL 11805527 T PL11805527 T PL 11805527T PL 2621477 T3 PL2621477 T3 PL 2621477T3
Authority
PL
Poland
Prior art keywords
mesalazine
obtaining
oral pharmaceutical
pharmaceutical tablet
controled release
Prior art date
Application number
PL11805527T
Other languages
English (en)
Inventor
Blas David Loeches
Fernández-Molina Roberto Varas
Pérez Mercedes Martínez
Original Assignee
Liconsa Laboratorios Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liconsa Laboratorios Sa filed Critical Liconsa Laboratorios Sa
Publication of PL2621477T3 publication Critical patent/PL2621477T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11805527T 2010-12-27 2011-12-23 Doustna tabletka farmaceutyczna do kontrolowanego uwalniania mesalazyny i sposób jej wytwarzania PL2621477T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382355A EP2468264A1 (en) 2010-12-27 2010-12-27 Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
PCT/EP2011/073983 WO2012089677A1 (en) 2010-12-27 2011-12-23 Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
EP11805527.6A EP2621477B1 (en) 2010-12-27 2011-12-23 Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it

Publications (1)

Publication Number Publication Date
PL2621477T3 true PL2621477T3 (pl) 2014-08-29

Family

ID=43901549

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11805527T PL2621477T3 (pl) 2010-12-27 2011-12-23 Doustna tabletka farmaceutyczna do kontrolowanego uwalniania mesalazyny i sposób jej wytwarzania

Country Status (17)

Country Link
US (1) US20130273156A1 (pl)
EP (2) EP2468264A1 (pl)
JP (1) JP2014501267A (pl)
CN (1) CN103269691A (pl)
BR (1) BR112013016461A2 (pl)
CA (1) CA2822754A1 (pl)
DK (1) DK2621477T3 (pl)
ES (1) ES2463040T3 (pl)
HK (1) HK1184391A1 (pl)
HR (1) HRP20140479T1 (pl)
PL (1) PL2621477T3 (pl)
PT (1) PT2621477E (pl)
RS (1) RS53363B (pl)
RU (1) RU2013125148A (pl)
SA (1) SA111330110B1 (pl)
SI (1) SI2621477T1 (pl)
WO (1) WO2012089677A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI688411B (zh) * 2013-02-22 2020-03-21 日商志瑞亞新藥工業股份有限公司 腸溶錠
CN103211780B (zh) * 2013-04-17 2015-10-14 沈阳药科大学 美沙拉嗪口服结肠定位粘附微丸
CA2968977A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUB20160203A1 (it) * 2016-01-19 2017-07-19 Valpharma Int Spa Formulazioni in compresse a rilascio modificato contenenti Mesalazina ad alto dosaggio, processo per la loro preparazione e loro uso.
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
RU2738114C2 (ru) 2016-04-19 2020-12-08 Конарис Рисёрч Инститьют Аг Пероральные фармацевтические композиции никотинамида
AU2017252410A1 (en) * 2016-04-19 2018-11-01 Ferring B.V. Oral pharmaceutical compositions of mesalazine
CN105902500B (zh) * 2016-04-27 2019-11-29 上海理工大学 一种美沙拉嗪肠溶定位控释制剂及其制备方法
UA127349C2 (uk) * 2017-06-21 2023-07-26 Мінерва Ньюросаєнсиз, Інк. Кишковорозчинна лікарська форма для перорального застосування з контрольованим вивільненням
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011120A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
IT202000011050A1 (it) * 2020-05-14 2021-11-14 Mogon Pharmaceuticals Sagl Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692484B1 (fr) * 1992-06-22 1995-06-30 Gouchet Franck Nouvelle forme galenique de 4-asa a liberation controlee.
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
SG147450A1 (en) * 2003-10-29 2008-11-28 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AU2005256653B2 (en) * 2004-06-28 2010-10-14 Solvay Pharmaceuticals B.V. Oral sustained release formulation of tedisamil with gastric retention properties
PT1781292E (pt) * 2004-07-15 2010-12-23 Abbott Healthcare Products Bv Formulação de libertação prolongada de 3-amino-8-{1-piperazinil)- 2h-1-benzopirano-2-ona
JP5041774B2 (ja) * 2006-09-22 2012-10-03 日本ケミファ株式会社 メサラジンを有効成分として含有する徐放性錠剤

Also Published As

Publication number Publication date
SI2621477T1 (sl) 2014-07-31
CA2822754A1 (en) 2012-07-05
US20130273156A1 (en) 2013-10-17
WO2012089677A1 (en) 2012-07-05
CN103269691A (zh) 2013-08-28
RU2013125148A (ru) 2015-02-10
EP2621477A1 (en) 2013-08-07
SA111330110B1 (ar) 2014-08-11
EP2468264A1 (en) 2012-06-27
RS53363B (en) 2014-10-31
DK2621477T3 (da) 2014-06-16
HRP20140479T1 (hr) 2014-07-04
EP2621477B1 (en) 2014-03-19
PT2621477E (pt) 2014-05-30
ES2463040T3 (es) 2014-05-27
JP2014501267A (ja) 2014-01-20
BR112013016461A2 (pt) 2016-09-27
HK1184391A1 (en) 2014-01-24

Similar Documents

Publication Publication Date Title
PL2621477T3 (pl) Doustna tabletka farmaceutyczna do kontrolowanego uwalniania mesalazyny i sposób jej wytwarzania
CY2020008I1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
HK1255336A1 (zh) 藥物製劑及其製備方法
IL220037A0 (en) Compressible-coated pharmaceutical composiitons and tablets and methods of manufacture
PL2595597T3 (pl) Urządzenie i sposób kapsułkowania kapsułek lub innych stałych postaci leku w kapsułkach
EP2448406A4 (en) ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN WITH DELAYED RELEASE AND METHOD OF USE THEREOF
IL216526A (en) A pharmaceutical dosage form is heat-dissolved and a method of preparing such a pharmaceutical dosage form
IL219276A0 (en) Gastroretentive dosage forms of poorly soluble drugs
EP2502199A4 (en) METHOD AND DEVICE FOR CONFORMITY REVIEW IN THE ADMINISTRATION OF MEDICAMENTS
EP2564845A4 (en) MEDICINE FOR TREATING HYPERPLASIC AND INFLAMMATORY DISORDERS IN HUMANS BASED ON DIINDOLYLMETHANE
ZA201402864B (en) A gastroretentive dosage system and process of preparation thereof
HK1183228A1 (zh) 口服藥物治療方法和組合物
IL225606A0 (en) A method for preparing an inactive supplement suitable for pharmaceutical use
PT2665471T (pt) Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
HUE037197T2 (hu) Javított kioldódású meszalazin tabletta
HK1214519A1 (zh) 雙用途硫酸鹽口服藥物組合物片劑及其使用方法
ZA201304731B (en) Pharmaceutical composites of poorly water soluble drugs and polymers
PL2692662T3 (pl) Kapsułka i urządzenie do przetwarzania kapsułki
EP2760435A4 (en) AUTHENTICABLE COATINGS FOR PHARMACEUTICAL TABLETS AND INGREDIENTS
SI2654723T1 (sl) Trdne farmacevtske dozirna oblike, ki obsegajo tadalafil in metode za njihovo pripravo
PL2561864T3 (pl) Tabletka powlekana zawierająca tianeptynę i sposób jej otrzymywania
ZA201303663B (en) Apparatus for conducting oral care experiments and method of forming and using the same
BR112013014963A2 (pt) comprimido farmacêutico de liberação controlada para administração oral
PL2651390T3 (pl) Orodyspersyjna tabletka farmaceutyczna na bazie zolpidemu
HU1000215D0 (en) Pharmaceutical composition containing nanostructured telmisartan and process for producing it